Keytruda approved as monotherapy in China for NSCLC

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

The National Medical Products Administration in China approved Merck’s Keytruda as monotherapy for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer whose tumors express PD-L1, with no EGFR or ALK genomic tumor aberrations.

Keytruda is the first anti-PD-1 therapy approved in China as both monotherapy and in combination with chemotherapy for the first-line treatment of patients with NSCLC.

Table of Contents

YOU MAY BE INTERESTED IN

Login